Replication-competent herpes simplex virus
US6509020B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 22, 1999 |
| Grant date | Jan 21, 2003 |
| Priority date | — |
| Expiry date | Sep 22, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16661
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A promising approach for the therapeutic treatment of brain tumors utilizes replication-competent, neuroattenuated herpes simplex virus-1 (HSV-1) mutants. This approach requires mutation of HSV-1 to eliminate killing of normal, non-dividing cells of the brain (e.g., neurons). The present invention discloses methods for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the gamma 34.5 gene and the uracil DNA glycosylase (UNG) gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and is not neurovirulent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.